Table 1.

Characteristics of the subjects at baseline (full analysis set)

CharacteristicArm 1, n=113Arm 2, n=34Arm 3, n=34Arm 4, n=116Arm 5, n=104
Age, yr
 Median74.071.075.075.071.5
 Interquartile range65–8062–7767–7967–7864–77
Women, no. (%)44 (38.9)15 (41.1)12 (35.3)38 (32.8)33 (31.7)
Race,a no. (%)
 White103 (91.2)30 (88.2)32 (94.1)107 (92.2)94 (90.4)
 Black5 (4.4)3 (8.8)05 (4.3)3 (2.9)
 Other5 (4.5)1 (2.9)2 (5.8)4 (3.5)7 (6.7)
Body mass indexb
 Median28.330.428.728.128.3
 Interquartile range26–3324–3526–3326–3226–33
GFR,c ml/min per 1.73 m2
 Median59.562.861.261.363.6
 Interquartile range44–7947–7948–7548–7648–83
Medical history,d no. (%)
 CKD42 (37.2)19 (55.9)15 (44.1)44 (37.9)40 (38.5)
 AKI23 (20.4)7 (20.6)10 (29.4)20 (17.2)28 (26.9)
 Hypertension83 (73.5)24 (70.6)24 (70.6)105 (90.5)88 (84.6)
 Cardiac failure49 (43.4)17 (50.0)18 (52.9)47 (40.5)55 (52.9)
 Ischemic heart disease86 (76.1)28 (82.4)26 (76.5)91 (78.4)80 (76.9)
 Cardiac arrhythmia48 (42.5)17 (50.0)9 (26.5)50 (43.1)39 (37.5)
 Cerebrovascular disorder19 (16.8)7 (20.6)5 (14.7)26 (22.4)23 (22.1)
 Diabetes mellitus60 (53.1)18 (52.9)16 (47.1)55 (47.4)51 (49.0)
  • Arm 1 indicates placebo. Arm 2 =0.02-mg/kg preoperative and postoperative doses. Arm 3 =0.12-mg/kg preoperative and 0.02-mg/kg postoperative doses. Arm 4 =0.46-mg/kg preoperative and 0.02-mg/kg postoperative doses. Arm 5 =0.46-mg/kg preoperative and postoperative doses.

  • a Race was self-reported.

  • b The body mass index is the weight in kilograms divided by the square of the height in meters.

  • c The GFR was estimated using the four-variable Modification of Diet in Renal Disease formula.

  • d These data were derived from the clinical database using narrow Standardized Medical Dictionary for Regulatory Activities Queries. AKI was collected using the renal failure query, cerebrovascular disorders were collected using the cerebrovascular nervous system disorders query, and diabetes mellitus was collected using the hyperglycemia/new-onset diabetes mellitus query.